Earnings Presentation Materials for the First Quarter of the Fiscal Year Ending March 2027 | Qol Holdings Co.,Ltd. (3034) timely disclosure

Worth reading

79Important

Scored from 4 of 6 sections

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

2591

¥ millions (year-on-year change in operating income)

Wording

Conditional

How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFirst quarter of the fiscal year ending March 20279 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥73,912 million+3.0%

Operating profit¥6,183 million+72.1%

Ordinary income¥6,159 million+69.5%

Net income¥3,002 million +61.7%profit attributable to owners of the parent

Selling, general and administrative expenses¥6,842 million

Operating profit margin

Rate8.4%

Results for the three months of the current quarterNet sales: ¥73,912 million; EBITDA: ¥8,757 million; operating income: ¥6,183 million; ordinary income: ¥6,159 million; quarterly net income attributable to owners of the parent: ¥3,002 million

Full-year earnings forecast

Net Sales

¥315,000 million

EBITDA

¥28,700 million

Operating profit

¥16,500 million

Ordinary income

¥16,500 million

Profit attributable to owners of the parent

¥7,800 million

Earnings per share

¥207.57

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。

Net Sales23.5%

EBITDA30.5%

Operating profit37.5%

Ordinary income37.3%

Profit attributable to owners of parent for the quarter38.5%

Quarterly earnings per share38.5%

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Net Sales

Prescription processing+¥700 million

Other merchandise sales+¥200 million

BPO business+¥0.3 billion

Pharmaceutical business+¥1 billion

Operating profit

Pharmacy business-¥0.0 billion

BPO business+¥100 million

Pharmaceutical business+¥2.6 billion

Adjustments and otherDown ¥100 million

New initiatives

Launch of 2 products containing 1 AG ingredient in June 2026
Launch of 2 products containing 1 generic-drug ingredient in July 2026
M&A and new store openings, mainly in the Tokyo, Nagoya and Osaka areas
Expansion of Lawson Qol pharmacy stores

Key KPIsA metric the company considers important as a management benchmark.

Shipment volume of key products+5% year on year
Year on year against the same period last year+5%
Number of dispatched medical representativesIncreased
Number of domestic CMRs4,205 People
Outsourcing ratio9.6 %
Number of Lawson Qol pharmacy stores50 Location

Unit price and quantity metricsThese figures show sales broken down by price and volume.

Number of Prescriptions Filled

Existing stores

2,813 thousand prescriptions-3.0%

All Stores

4,079 thousand prescriptions-2.3%

Prescription Unit Price

Existing stores

¥10,937+1.7%

All Stores

¥9,864+4.0%

Segment results

Pharmacy business

Net Sales

¥43,694 million+2.0%

Segment profit

¥1,669 million-4.7%

BPO business

Net Sales

¥3,836 million+10.1%

Segment profit

¥649 million+31.5%

Pharmaceutical business

Net Sales

¥26,381 million+3.8%

Segment profit

¥4,940 million+113.3%

Market Size / Share

Number of domestic CMRs

4,205 People

Outsourcing ratio

9.6 %

Number of stores and locations

Number of Stores at Period-End949 Location

Stores opened during the period4 Location

Number of M&A transactions during the period0 Location

Number of stores sold during the period0 Location

Annual Dividend

Annual dividend per share¥54

Interim¥27

End of period¥27

Payout ratio

Rate26.0%

Contents of this document
Item	Details
Document type	Presentation materials for financial results
Fiscal Period Covered	First quarter of the fiscal year ending March 2027
Net Sales	¥73,912 million (YoY +3.0%)
Operating profit	¥6,183 million (YoY +72.1%)
Ordinary income	¥6,159 million (YoY +69.5%)
Net income	¥3,002 million (profit attributable to owners of the parent) (YoY +61.7%)
Operating profit margin	Rate 8.4% / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses	¥6,842 million
Results for the three months of the current quarter	Net sales: ¥73,912 million; EBITDA: ¥8,757 million; operating income: ¥6,183 million; ordinary income: ¥6,159 million; quarterly net income attributable to owners of the parent: ¥3,002 million
Full-year earnings forecast	Net Sales ¥315,000 million / EBITDA ¥28,700 million / Operating profit ¥16,500 million / Ordinary income ¥16,500 million / Profit attributable to owners of the parent ¥7,800 million / Earnings per share ¥207.57
Progress against full-year forecast	Net Sales 23.5% / EBITDA 30.5% / Operating profit 37.5% / Ordinary income 37.3% / Profit attributable to owners of parent for the quarter 38.5% / Quarterly earnings per share 38.5%
Segment results	Pharmacy business Net Sales ¥43,694 million (YoY +2.0%) / Segment profit ¥1,669 million (YoY -4.7%) / BPO business Net Sales ¥3,836 million (YoY +10.1%) / Segment profit ¥649 million (YoY +31.5%) / Pharmaceutical business Net Sales ¥26,381 million (YoY +3.8%) / Segment profit ¥4,940 million (YoY +113.3%)
Breakdown of Factors Affecting the Change	Net Sales Prescription processing +¥700 million / Other merchandise sales +¥200 million / BPO business +¥0.3 billion / Pharmaceutical business +¥1 billion / Operating profit Pharmacy business -¥0.0 billion / BPO business +¥100 million / Pharmaceutical business +¥2.6 billion / Adjustments and other Down ¥100 million
Key KPIs	Indicator name Shipment volume of key products / Value +5% year on year / Year on year against the same period last year +5%, Indicator name Number of dispatched medical representatives / Value Increased / Year on year against the same period last year Not disclosed, Indicator name Number of domestic CMRs / Value 4,205 People / Year on year against the same period last year Not disclosed, Indicator name Outsourcing ratio / Value 9.6 % / Year on year against the same period last year Not disclosed, Indicator name Number of Lawson Qol pharmacy stores / Value 50 Location / Year on year against the same period last year Not disclosed
Unit price and quantity metrics	Number of Prescriptions Filled Existing stores 2,813 thousand prescriptions (YoY -3.0%) / All Stores 4,079 thousand prescriptions (YoY -2.3%) / Prescription Unit Price Existing stores ¥10,937 (YoY +1.7%) / All Stores ¥9,864 (YoY +4.0%)
Number of stores and locations	Number of Stores at Period-End 949 Location / Stores opened during the period 4 Location / Number of M&A transactions during the period 0 Location / Number of stores sold during the period 0 Location
Annual Dividend	Annual dividend per share ¥54 / Interim ¥27 / End of period ¥27
Payout ratio	Rate 26.0% / Total payout ratio Not disclosed / DOE Not disclosed
Market Size / Share	Number of domestic CMRs 4,205 People / Outsourcing ratio 9.6 %
New initiatives	Launch of 2 products containing 1 AG ingredient in June 2026, Launch of 2 products containing 1 generic-drug ingredient in July 2026, M&A and new store openings, mainly in the Tokyo, Nagoya and Osaka areas, Expansion of Lawson Qol pharmacy stores

Items this document does not state (11)

Gross Profit MarginSelf-assessment against the planNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In the Pharmaceutical Business, products launched in the fiscal year ended March 2026 and new products launched during the current fiscal year contributed to results, while costs for existing products were also reduced. In the BPO Business, the number of dispatched medical representatives increased against a backdrop of growing demand for their services. In the Pharmacy Business, the average technical fee per prescription increased, but the number of prescriptions processed declined due to factors including longer prescription periods.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.